CCCharles E. Chalfant

Charles E. Chalfant

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Charles E. Chalfant has a total of 92 co-authors. Here are the top co-authors by number of shared publications:

  • Dayanjan S. Wijesinghe

    Department of Surgery Virginia Commonwealth University-School of Medicine, Richmond, VA 23298 Hunter Holmes McGuire Veterans Administration Medical Center, Richmond, VA 23249

    11 shared publications
  • Jacqueline C. Shultz

    The ¶Department of Biochemistry and Biophysics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104

    6 shared publications
  • Lauren Alexis Hoeferlin

    Department of Biochemistry and Molecular Biology, Virginia Commonwealth University-School of Medicine, Richmond VA 23298, USA

    6 shared publications
  • Nadia F. Lamour

    Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, Virginia 23298, USA

    6 shared publications
  • Jennifer A. Mietla

    Department of Biochemistry and Molecular Biology, Virginia Commonwealth University-School of Medicine, Richmond, VA 23298

    4 shared publications
  • Autumn Massiello

    Department of Biochemistry, Virginia Commonwealth University, Richmond, Virginia 23298

    3 shared publications

Latest Publications

  • Exogenous ceramide-1-phosphate (C1P) and phospho-ceramide analogue-1 (PCERA-1) regulate key macrophage activities via distinct receptors

    by Sebastián Katz, Orna Ernst, Dorit Avni, Muhammad Athamna, Amir Philosoph, Lide Arana, Alberto Ouro, L. Alexis Hoeferlin, Michael M. Meijler, Charles E. Chalfant, et al.


  • Open Access

    The Alternative Splicing of Cytoplasmic Polyadenylation Element Binding Protein 2 Drives Anoikis Resistance and the Metastasis of Triple Negative Breast Cancer

    by Ryan M. Johnson, Ngoc T. Vu, Brian P. Griffin, Amanda E. Gentry, Kellie J. Archer, Charles E. Chalfant, Margaret A. Park


  • Open Access

    Ceramide kinase is required for a normal eicosanoid response and the subsequent orderly migration of fibroblasts

    by Dayanjan S. Wijesinghe, Matthew Brentnall, Jennifer A. Mietla, L. Alexis Hoeferlin, Robert F. Diegelmann, Lawrence H. Boise, Charles E. Chalfant


    • 11 November 2013
      • Vol. 1  (1) , 3-7

    Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer

    by L. Alexis Hoeferlin, Charles E.Chalfant, Margaret A. Park

    While the 5-year survival rate of breast cancer is at an all-time high of 90%, this disease remains the second most common cause of cancer-related death, surpassed only by lung cancer in the US. The reasons for this discrepancy stem from cancer subtypes which become resistant to current therapies. These subtypes: “Triple negative” and ErbB2-overexpressing, are discussed in this review.


  • Open Access

    Non-vesicular trafficking by a ceramide-1-phosphate transfer protein regulates eicosanoids

    by Dhirendra K. Simanshu, Ravi Kanth Kamlekar, Dayanjan S. Wijesinghe, Xianqiong Zou, Xiuhong Zhai, Shrawan K. Mishra, Julian G. Molotkovsky, Lucy Malinina, Edward H. Hinchcliffe, Charles E. Chalfant, et al.

    A human lipid transfer protein (GLTPD1, named here CPTP) is shown to regulate eicosanoid production by mediating the intermembrane transfer of the phosphorylated sphingolipid ceramide-1-phosphate through a non-vesicular transport mechanism elucidated by structural, functional and biological data. The bioactive signalling lipid ceramide-1-phosphate (C1P) regulates diverse processes ranging from growth and survival to pro-inflammatory responses. In this study, Dinshaw Patel and colleagues address how C1P is transported to specific sites in the cell. A novel lipid transfer protein called ceramide-1-phosphate transfer protein (CPTP) was identified, and structural and functional studies reveal the mechanism by which C1P is transported from its site of synthesis in the Golgi complex to the plasma membrane. Phosphorylated sphingolipids ceramide-1-phosphate (C1P) and sphingosine-1-phosphate (S1P) have emerged as key regulators of cell growth, survival, migration and inflammation1,2,3,4,5. C1P produced by ceramide kinase is an activator of group IVA cytosolic phospholipase A2α (cPLA2α), the rate-limiting releaser of arachidonic acid used for pro-inflammatory eicosanoid production3,6,7,8,9, which contributes to disease pathogenesis in asthma or airway hyper-responsiveness, cancer, atherosclerosis and thrombosis. To modulate eicosanoid action and avoid the damaging effects of chronic inflammation, cells require efficient targeting, trafficking and presentation of C1P to specific cellular sites. Vesicular trafficking is likely10 but non-vesicular mechanisms for C1P sensing, transfer and presentation remain unexplored11,12. Moreover, the molecular basis for selective recognition and binding among signalling lipids with phosphate headgroups, namely C1P, phosphatidic acid or their lyso-derivatives, remains unclear. Here, a ubiquitously expressed lipid transfer protein, human GLTPD1, named here CPTP, is shown to specifically transfer C1P between membranes. Crystal structures establish C1P binding through a novel surface-localized, phosphate headgroup recognition centre connected to an interior hydrophobic pocket that adaptively expands to ensheath differing-length lipid chains using a cleft-like gating mechanism. The two-layer, α-helically-dominated ‘sandwich’ topology identifies CPTP as the prototype for a new glycolipid transfer protein fold13 subfamily. CPTP resides in the cell cytosol but associates with the trans-Golgi network, nucleus and plasma membrane. RNA interference-induced CPTP depletion elevates C1P steady-state levels and alters Golgi cisternae stack morphology. The resulting C1P decrease in plasma membranes and increase in the Golgi complex stimulates cPLA2α release of arachidonic acid, triggering pro-inflammatory eicosanoid generation.


  • Open Access

    Characterization of eicosanoid synthesis in a genetic ablation model of ceramide kinase

    by Jennifer A. Mietla, Dayanjan S. Wijesinghe, L. Alexis Hoeferlin, Michael D. Shultz, Ramesh Natarajan, Alpha A. Fowler, Charles E. Chalfant


  • Open Access

    OSU-03012 sensitizes breast cancers to lapatinib-induced cell killing: a role for Nck1 but not Nck2

    by N Winston West, Aileen Garcia-Vargas, Charles E Chalfant, Margaret A Park

    Background: Lapatinib is characterized as an ErbB1/ErbB2 dual inhibitor and has recently been approved for the treatment of metastatic breast cancer. In this study, we examined mechanisms associated with enhancing the activity of lapatinib via combination with other therapies. Methods: In the present studies, estrogen receptor (ER) positive and ER negative breast cancer cells were genetically manipulated to up- or downregulate eIF2-alpha, its phospho-mutant, Nck1, or Nck2, then treated with OSU-03012, lapatinib or the combination and assayed for cytotoxicity/cytostaticity using clonogenic assays. Results: Treatment of breast cancer cell lines with lapatinib and OSU-03012 (a small molecule derivative of the Cox-2 inhibitor celecoxib) induced synergistic cytotoxic/cytostatic effects. This combination therapy corresponded to an increase in the phosphorylation of eIF2-α at serine51 and a decrease in Nck1 expression. Ectopic expression of phospho-mutant eIF2-α (Ser51Ala) or downregulation of eIF2-α in addition to downregulation of the eIF2-α kinase PERK inhibited the synergistic and cytotoxic effects. Furthermore, ectopic expression of Nck1, but not Nck2 abolished the decrease in cell viability observed in combination-treated cells. Downregulation of Nck1 failed to “rescue” the ablation of the cytotoxic/cytostatic effects by the phospho-mutant of eIF2-α (Ser51Ala) demonstrating that Nck1 downregulation is upstream of eIF2-α phosphorylation in the anti-survival pathway activated by lapatinib and OSU-03012 treatment. Finally, co-immunoprecipitation assays indicated that eIF2-α dissociates from the Nck1/PP1 complex after OSU-03012 and lapatinib co-treatment. Conclusions: These data indicate that OSU-03012 and lapatinib co-treatment is an effective combination therapy, which functions to enhance cell killing through the Nck1/eIF2 complex. Hence, this complex is a novel target for the treatment of metastatic breast cancer.


  • The Role of Ceramide-1-Phosphate in Biological Functions

    by L. Alexis Hoeferlin, Dayanjan S. Wijesinghe, Charles E. Chalfant

    In mammalian cells, cermide-1-phosphate (C1P) is produced via the ATP-dependent mechanism of converting ceramide to C1P by the enzyme, ceramide kinase (CERK). CERK was first described as a calcium-stimulated lipid kinase that co-purified with brain synaptic vesicles, and to date, CERK is the only identified mammalian enzyme known to produce C1P in cells. C1P has steadily emerged as a bioactive sphingolipid involved in cell proliferation, macrophage migration, and inflammatory events. The recent generation of the CERK knockout mouse and the development of CERK inhibitors have furthered our current understanding of CERK-derived C1P in regulating biological processes. In this chapter, the history of C1P as well as the biological functions attributed to C1P are reviewed.


  • Open Access

    hnRNP U Enhances Caspase-9 Splicing and Is Modulated by AKT-dependent Phosphorylation of hnRNP L

    by Ngoc T. Vu, Margaret A. Park, Jacqueline C. Shultz, Rachel W. Goehe, L. Alexis Hoeferlin, Michael D. Shultz, Sarah A. Smith, Kristen W. Lynch, Charles E. Chalfant


  • Metallofullerene-Nanoplatform-Delivered Interstitial Brachytherapy Improved Survival in a Murine Model of Glioblastoma Multiforme

    by John D. Wilson, William C. Broaddus, Harry C. Dorn, Panos P. Fatouros, Charles E. Chalfant, Michael D. Shultz

    Fullerenes are used across scientific disciplines because of their diverse properties gained by altering encapsulated or surface-bound components. In this study, the recently developed theranostic agent based on a radiolabeled functionalized metallofullerene (177Lu-DOTA-f-Gd3N@C80) was synthesized with high radiochemical yield and purity. The efficacy of this agent was demonstrated in two orthotopic xenograft brain tumor models of glioblastoma multiforme (GBM). A dose-dependent improvement in survival was also shown. The in vivo stability of the agent was verified through dual label measurements of biological elimination from the tumor. Overall, these results provide evidence that nanomaterial platforms can be used to deliver effective interstitial brachytherapy.